We noticed JavaScript is turned off in your browser settings. For a better viewing experience, enable JavaScript. If you're unsure of how to do this, click here to download a new browser.


Odelia B. Cooper, MD

Cedars-Sinai Pituitary Center
127 S. San Vicente Blvd.
Advanced Health Sciences Pavilion, Suite A6600
Los Angeles, CA 90048





Diabetes Outpatient Treatment and Education Center
8723 Alden Drive
Steven Spielberg Building, Suite 250
Los Angeles, CA 90048





Odelia B. Cooper, MD

  • IM/Endocrinology

Calcium Disorders

Cushing's Disease

Diabetes Mellitus (Type 1 & 2)




Insulin Pump Therapy

PCOS (Polycystic Ovary Syndrome)

Parathyroid Disorders

Pituitary Disorders

Pituitary Tumors


Thyroid Cancers

Thyroid Disorders

The research of Odelia B. Cooper, MD, focuses on pituitary tumors, with the goal of understanding signaling pathways contributing to pituitary tumorigenesis in order to develop new therapies targeting recurrent tumor growth and invasion. Based on her work on a rare subset of aggressive tumors, Cooper began to investigate mechanisms by which pituitary tumors progress from noninvasive to invasive behavior. This led to her interest in the ErbB pathway to see if these receptors play an active role in pituitary tumorigenesis. Cooper is now validating clinical response of patients with aggressive tumors to ErbB targeted therapy.

  • Undergraduate: Johns Hopkins University, 1998
  • Medical School: Johns Hopkins University School of Medicine, 2002
  • Residency: Cedars-Sinai, 2006
  • Fellowship: Cedars-Sinai, 2008
  • Fellowship: Cedars-Sinai, 2009
  • Recipient of NIH K23 Career Development Award
  • Member, Endocrine Society and Pituitary Society
  • Recipient of Outstanding PBL Tutor Award, UCLA
  • Recipient of NIDDK R21 Grant
  • Schell MJ, Cooper OB, Snyder SH. D-aspartate localizations imply neuronal and neuroendocrine roles. Proc Natl Acad Sci USA. 1997;(5):2013-2018.
  • Cooper O, Geller JL, Melmed S. Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nat Clin Pract Endocrinol Metab. 2008;(4):234-238.
  • Vlotides G, Cooper O, Chen YH, Ren SG, Greenman Y, Melmed S. Heregulin regulates prolactinoma gene expression. Cancer Res. 2009;(10):4209-4216.
  • Cooper O, Vlotides G, Fukuoka H, Greene MI, Melmed S. Expression and function of ErbB receptors and ligands in the pituitary. Endocr Relat Cancer. 2011;18(6):R197-R211.
  • Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long term outcomes. Horm Cancer. 2010;1(1):80-92.
  • Cooper O, Mamelak A, Bannykh S, Carmichael JD, Bonert V, Lim S, Cook-Wiens G, Ben-Shlomo A. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine. 2014;46(2):318-327.

Show moreShow less


Make an Appointment




Available 24 Hours A Day


Send Email to Odelia B. Cooper, MD